UBS Raises PT on Iovance Biotherapeutics (IOVA)

​The improved terms people is based connected cardinal improvements successful fiscal Q4 2025; however, Amtagvi acceleration remains uncertain, said the expert successful his probe note. The institution reported fiscal Q4 2025 net connected February 24. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) grew its quarterly gross by 17.74% year-over-year to $86.77 cardinal and topped estimates by $5.76 million. The EPS for the 4th came successful astatine antagonistic $0.18 but stayed successful enactment with the consensus.

​Management attributed maturation to beryllium driven by the commercialization of AMTAGVI successful precocious melanoma. The cause witnessed accelerated uptake crossed some world and assemblage attraction centers. Full-year merchandise gross reached $264 million, driven by a 112% year-over-year summation successful AMTAGVI revenue.

​Management noted that the fiscal 2026 gross guidance volition beryllium provided successful the adjacent future.

​Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is simply a commercial-stage biopharmaceutical institution that develops and commercializes compartment therapies utilizing autologous tumor-infiltrating lymphocytes for the attraction of metastatic melanoma and different coagulated tumor cancers successful the US and internationally.

While we admit the imaginable of IOVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey connected Google News.